Absence of germline BRCA1 mutations in familial pancreatic cancer patients

Cancer Biology and Therapy

Volumn 8, Issue 2, 2009, Pages 131-135

  Axilbund, Jennifer E ^a   Argani, Pedram ^a,b   Kamiyama, Mihoko ^b   Palmisano, Emily ^b   Raben, Marian ^a   Borges, Michael ^b   Brune, Kieran A ^b   Goggins, Michael ^a,b   Hruban, Ralph H ^a,b   Klein, Alison P ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

BRCA1; Familial pancreatic cancer; Genetic counseling; Inherited cancer syndromes; Risk assessment

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVARY CANCER; PANCREAS CANCER; RISK FACTOR;

EID: 58749112549     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.2.7136     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996; 23:251-75.
3. Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J 2001; 7:266-73.
4. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64:2634-8.
5. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789-93.
6. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214-21.
7. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:342-6.
8. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-4.
9. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154:1835-40.
10. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970-4.
11. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87:809-11.
12. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14:141-5.
13. Whitcomb DC, Preston RA, Aston CE, et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996; 110:1975-80.
14. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358-65.
15. Cancer risks in BRCA2 mutation carriers.The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91:1310-6.
16. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365-72.
17. Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005; 158:119-25.
18. Dagan E. Predominant Ashkenazi BRCA1/2 Mutations in Families with Pancreatic Cancer. Genet Test 2008.
19. Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1 and BRCA2 mutations. Cancer Res 2000; 60:409-16.
20. Al-Sukhni W, Rothenmund H, Eppel Borgida A, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet 2008.
21. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11:5175-80.
22. Lakhani SR, Van DV, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310-8.
23. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006; 24:707-15.
24. Tai YC, Chen S, Parmigiani G, et al. Incorporating Tumor Immunohistochemical Markers in BRCA1 and BRCA2 Carrier Prediction. Vol 10. Breast Cancer Research 2008; 401.
25. Klein AP, Beaty TH, Bailey-Wilson JE, et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002; 23:133-49.
26. Matsubayashi H, Fukushima N, Sato N, et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther 2003; 2:652-5.
27. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45.
28. Axilbund JE, Brune KA, Canto MI, et al. Patient Perspective on the Value of Genetic Counseling for Familial Pancreas Cancer. Hereditary Cancer in Clinical Practice 2005; 3:115-22.
29. Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25:1417-22.
30. Canto M, Goggins M, Hruban R, et al. Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clin Gast Hepatol 2006.
31. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2:606-21.